Sugi Predict

Sugi Predict / Compounds / SCHEMBL8163166

SCHEMBL8163166

SCHEMBL8163166

CCOC(=O)N1CC[C@@H]2Nc3c(Br)cccc3[C@@H]2C1

nearest known ligand 0.43

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
▸ BRD4 O60885 3/20 0.43
▸ L3MBTL1 Q9Y468 1/20 0.40
▸ DPP4 P27487 1/20 0.39
▸ MEN1 O00255 2/20 0.38
▸ KMT2A Q03164 2/20 0.38
▸ GAA P10253 1/20 0.38
▸ NPSR1 Q6W5P4 1/20 0.38
▸ NOS2 P35228 1/20 0.38
▸ KDM4E B2RXH2 1/20 0.38
▸ LMNA P02545 1/20 0.38
▸ ALDH1A1 P00352 1/20 0.37
▸ POLB P06746 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22054365 1.00 BRD4 (0.43) BRD4L3MBTL1DPP4MEN1KMT2A
SCHEMBL21379804 1.00 BRD4 (0.43) BRD4L3MBTL1DPP4MEN1KMT2A
SCHEMBL21037265 1.00 BRD4 (0.43) BRD4L3MBTL1DPP4MEN1KMT2A
SCHEMBL30641160 1.00 BRD4 (0.43) BRD4L3MBTL1DPP4MEN1KMT2A
SCHEMBL28982269 1.00 BRD4 (0.43) BRD4L3MBTL1DPP4MEN1KMT2A
SCHEMBL29963891 1.00 BRD4 (0.43) BRD4L3MBTL1DPP4MEN1KMT2A
SCHEMBL22066428 0.87 DPP4 (0.46) BRD4L3MBTL1DPP4MEN1KMT2A
SCHEMBL8149597 0.87 DPP4 (0.46) BRD4L3MBTL1DPP4MEN1KMT2A
SCHEMBL8158624 0.87 BRD4 (0.43) BRD4L3MBTL1DPP4MEN1KMT2A
SCHEMBL21391324 0.87 BRD4 (0.43) BRD4L3MBTL1DPP4MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 65 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-113024554-A Preparation method of rumepilone intermediate 上海法默生物科技有限公司 2021-06-25 — — CN claimed
EP-2134710-B1 SUBSTITUTED HETEROCYCLE FUSED GAMMA-CARBOLINES SYNTHESIS INTRA CELLULAR THERAPIES INC (US) 2020-02-12 — — EP claimed
US-20260098040-A1 SUBSTITUTED HETEROCYCLE FUSED GAMMA-CARBOLINES SYNTHESIS INTRA CELLULAR THERAPIES INC (US) 2026-04-09 — — US disclosed
EP-3768271-B1 ORGANIC COMPOUNDS INTRA CELLULAR THERAPIES INC (US) 2026-02-18 — — EP disclosed
EP-3609891-B1 SUBSTITUTED HETEROCYCLE FUSED GAMMA-CARBOLINES SYNTHESIS INTRA CELLULAR THERAPIES INC (US) 2026-02-11 — — EP disclosed
US-20250388581-A1 ORGANIC COMPOUNDS INTRA CELLULAR THERAPIES INC (US) 2025-12-25 — — US disclosed
US-20250312340-A1 METHODS OF TREATING NEUROPATHIC PAIN INTRA-CELLULAR THERAPIES, INC. 2025-10-09 — — US disclosed
EP-3898581-B1 SUBSTITUTED HETEROCYCLE FUSED GAMMA-CARBOLINES SYNTHESIS INTRA CELLULAR THERAPIES INC (US) 2025-08-27 — — EP disclosed
US-12364694-B2 Organic compounds INTRA-CELLULAR THERAPIES, INC. (US) 2025-07-22 — — US disclosed
US-12358916-B2 Substituted heterocycle fused gamma-carbolines synthesis INTRA-CELLULAR THERAPIES, INC. (US) 2025-07-15 — — US disclosed
US-12331052-B2 Organic compounds INTRA-CELLULAR THERAPIES, INC. (US) 2025-06-17 — — US disclosed
US-8779139-B2 Substituted 2,3,4,4A,5,9B-hexahydro-1H-pyrido[4,3-B]indole derivatives synthesis and uses thereof INTRA-CELLULAR THERAPIES, INC. 2014-07-15 — — US disclosed
US-8779139-B2 Substituted 2,3,4,4A,5,9B-hexahydro-1H-pyrido[4,3-B]indole derivatives synthesis and uses thereof INTRA-CELLULAR THERAPIES, INC. 2014-07-15 — — US disclosed
US-20130046097-A1 SUBSTITUTED HETEROCYCLE GAMMA-CARBOLINES SYNTHESIS INTRA-CELLULAR THERAPIES, INC. 2013-02-21 — — US disclosed
US-20130046097-A1 SUBSTITUTED HETEROCYCLE GAMMA-CARBOLINES SYNTHESIS INTRA-CELLULAR THERAPIES, INC. 2013-02-21 — — US disclosed
US-8309722-B2 Substituted heterocycle gamma-carbolines synthesis INTRA-CELLULAR THERAPIES, INC. (US) 2012-11-13 — — US disclosed
US-8309722-B2 Substituted heterocycle gamma-carbolines synthesis INTRA-CELLULAR THERAPIES, INC. (US) 2012-11-13 — — US disclosed
US-20100113781-A1 SUBSTITUTED HETEROCYCLE GAMMA-CARBOLINES SYNTHESIS INTRACELLULAR THERAPIES, INC. (US) 2010-05-06 — — US disclosed
US-20100113781-A1 SUBSTITUTED HETEROCYCLE GAMMA-CARBOLINES SYNTHESIS INTRACELLULAR THERAPIES, INC. (US) 2010-05-06 — — US disclosed
WO-2008112280-A1 SUBSTITUTED HETEROCYCLE FUSED GAMMA-CARBOLINES SYNTHESIS INTRA-CELLULAR THERAPIES, INC. (US) 2008-09-18 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250312340-A1 METHODS OF TREATING NEUROPATHIC PAIN GAP43, OPRK1, CNR2 BRD4 1657/4885L3MBTL1 4510/4885DPP4 1289/4885
US-12358916-B2 Substituted heterocycle fused gamma-carbolines synthesis HCCS, CYCS, CBR3 BRD4 155/4885L3MBTL1 3545/4885DPP4 3481/4885
US-20250388581-A1 ORGANIC COMPOUNDS OPRD1, OPRM1, HTR2C BRD4 2633/4885L3MBTL1 1834/4885DPP4 1962/4885
US-12331052-B2 Organic compounds OPRD1, OPRK1, OPRM1 BRD4 2499/4885L3MBTL1 3475/4885DPP4 2134/4885
US-20100113781-A1 SUBSTITUTED HETEROCYCLE GAMMA-CARBOLINES SYNTHESIS CYCS, HCCS, CBR3 BRD4 123/4885L3MBTL1 3643/4885DPP4 3568/4885
US-20260098040-A1 SUBSTITUTED HETEROCYCLE FUSED GAMMA-CARBOLINES SYNTHESIS KCNH2, KCNH3, KCNH1 BRD4 1070/4885L3MBTL1 3279/4885DPP4 4152/4885
US-20130046097-A1 SUBSTITUTED HETEROCYCLE GAMMA-CARBOLINES SYNTHESIS CYCS, HCCS, CBR3 BRD4 123/4885L3MBTL1 3643/4885DPP4 3568/4885
US-12364694-B2 Organic compounds OPRD1, OPRK1, OPRM1 BRD4 2110/4885L3MBTL1 3356/4885DPP4 2027/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.